EGFR and cancer prognosis;Valeur pronostique du récepteur du facteur de croissance épidermique

Bulletin du Cancer

Volumn 90, Issue SPEC. ISS., 2003, Pages

  Penault Llorca, Frédérique ^a   Durando, Xavier ^a   Bay, Jacques Olivier ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

EGF; Epidermal growth factor; Malignant tumour; Prognostic factor; TGF alpha

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND;

ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER; CANCER THERAPY; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TARGETING; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; STANDARD; UTERINE CERVIX CANCER;

CARCINOMA, SQUAMOUS CELL; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0346874160     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
2. L'Allemain G. La famille des récepteurs HER-ErbB et ses ligands: mécanismes d'activation, signalisations et dérégulations dans le cancer. Bull Cancer 2003; 90 (numéro spécial): S179-85.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
4. Bosq J, Penault-Llorca F, Sabourin JC. Expression du récepteur à l'EGF et de ses ligands dans d'autres pathologies tumorales malignes. Bull Cancer 2003; 90 (numéro spécial): S242-5.
5. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-15.
6. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003; 5: 140-6.
7. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinoma. Head Neck 2001; 23: 147-59.
8. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999; 5: 577-86.
9. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996; 2: 909-14.
10. Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 2000; 19: 225-33.
11. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/ neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 119-29.
12. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253-7.
13. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-32.
14. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996; 106: 884-8.
15. Nikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 1997; 16: 60-8.
16. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17: 613-9.
17. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patient with American joint committee on cancer stage IV colon adenocarcinoma. Cancer 2001; 92: 1331-46.
18. Torregrosa D, Bolufer P, Lluch A, Lopez JA, Barragan E, Ruiz A, et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 1997; 262: 99-119.
19. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003; 133: 219-21.
20. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (suppl. 4): S3-8.
21. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001; 19: 3808-16.
22. Diéras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P, de Crémoux P. Le ciblage du récepteur à l'EGF (epidermal growth factor receptor) dans les cancers du sein. Bull Cancer 2003; 90 (numéro spécial): S258-62.
23. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, et al. Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 1994; 54: 1684-9.
24. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5,232 patients. Endocr Rev 1992; 13: 3-17.
25. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001; 12: 841-6.
26. Kopp R, Ruge M, Rothbauer E, Cramer C, Kraemling HJ, Wiebeck B, et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002; 22: 1161-7.
27. Garcia I, Vizoso F, Andicoechea A, Raigoso P, Verez P, Alexandre E, et al. Clinical significance of epidermal growth factor receptor content in gastric cancer. Int J Biol Markers 2001; 16: 183-8.
28. Yonemura Y, Takamura H, Ninomiya I, Fushida S, Tsugawa K, Kaji M, et al. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992; 49: 157-61.
29. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38: 2258-64.
30. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77: 1352-4.
31. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1: 97-105.
32. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998; 28: 971-9.
33. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975-81.
34. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50: 7077-80.
35. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002; 29 (suppl. 14): 31-7.
36. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-9.
37. Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73: 1913-8.
38. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15: 68-76.
39. Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003; 8: E1-13.
40. Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002; 52: 592-8.
41. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51: 410-8.
42. Kaulich K, Blaschke B, Numann A, von Deimling A, Wiestler OD, Weber RG, Reifenberger G. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. J Neuropathol Exp Neurol 2002; 61: 1092-9.
43. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, et al. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993; 71: 2902-9.
44. Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997; 17: 3841-7.
45. Bauknecht T, Janz I, Kohler M, Pfleiderer A. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F). Med Oncol Tumor Pharmacother 1989; 6: 121-7.
46. Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17: 1293-6.
47. Turkeri LN, Erton ML, Cevik I, Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 1998; 51: 645-9.
48. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 2002; 7 (suppl. 4): 2-8.
49. Arteaga CL. Epidermal growth factor receptor dependence in human tumor: more than just expression. The Oncologist 2002; 7 (suppl. 4): 31-9.
50. Milano G. Conséquences pharmacologiques du ciblage du REGF. Bull Cancer 2003; 90 (numéro spécial): S197-201.